Company Overview

Lupin is a global pharmaceutical company that operates in over 100 countries and employs more than 20,000 people. The company manages 15 state-of-the-art manufacturing facilities located in India, the US, Brazil, and Mexico. Lupin is a global leader in the Anti-Tuberculosis segment and offers a diverse array of products, including branded and generic formulations, biotech products, Active Pharmaceutical Ingredients (API), and specialty drugs.

Product Offerings

Lupin offers a wide range of products in key therapeutic areas such as diabetes, cardiology, respiratory, and ophthalmology. The company provides both branded and generic formulations, biotech products, APIs, and specialty drugs. Lupin's over-the-counter (OTC) products are marketed through divisions like LupinLife Consumer Care in India and Pharmacy Action in Australia. In response to the COVID-19 pandemic, Lupin launched Covihalt (Favipiravir) in India for the treatment of COVID-19 and Albuterol in the US, a key rescue inhalation product.

Manufacturing Facilities

Lupin operates 15 state-of-the-art manufacturing facilities that are strategically located across India, the US, Brazil, and Mexico. These facilities are integral to the company's ability to produce a wide array of pharmaceutical products, including APIs, generic formulations, and specialty drugs. The company's extensive manufacturing capabilities ensure the production of high-quality medications that meet global standards.

Corporate Social Responsibility

Lupin is deeply engaged in corporate social responsibility (CSR) activities, impacting 2.5 million lives across nine states. The company's CSR initiatives include healthcare, education, and community development projects aimed at improving the quality of life for underprivileged communities. Lupin also participated in global COVID-19 relief efforts by providing both monetary and material support, including contributions to the PM CARES Fund and other initiatives.

COVID-19 Response

In response to the COVID-19 pandemic, Lupin launched several initiatives to support global efforts against the virus. The company introduced Covihalt (Favipiravir) in India for the treatment of COVID-19 and Albuterol in the US, a key rescue inhalation product. Lupin also contributed to the PM CARES Fund and other relief efforts, providing monetary and material support to help combat the pandemic.

report flag Report inaccurate information

Lupin Employees

report flag Report inaccurate information

Companies similar to Lupin

Cipla is a global pharmaceutical company with a presence in over 80 countries, offering more than 1,500 products across various therapeutic categories. With a turnover of $2.8 billion and over 25,000 employees, Cipla is known for its significant contributions to respiratory, ARV, and cardio portfolios, particularly in Malaysia.

Cian, founded in 2003, is a pharmaceutical company offering a wide range of products and operating state-of-the-art manufacturing facilities. Recognized as one of the 'Top 100 SMEs of India,' Cian's products are available in over 15 markets globally.

People indexed